It is currently Fri Dec 19, 2014 11:25 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Positive data from multiple dose phase1 trial of CTP-354

Concert Pharmaceuticals Inc. announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. In this multiple ascending dose trial, no sedation or ataxia was observed with CTP-354 and the drug was generally well tolerated across all dose cohorts.

Concert expects to initiate a Phase 2 clinical trial evaluating CTP-354 in patients with spasticity associated with spinal cord injury by the end of 2014..... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Positive data from multiple dose phase1 trial of CTP-354 | Views : 353 | Replies : 0


Tecfidera versus aubagio

In brief, I was diagnosed with ms more than 20 years ago. Based on the treatments available then, I chose to wait as the disease was mostly a symptomatic. Now in my late 40's it has come back with a vengeance. MRI shows multiple lesions and I'm having multiple episodes especially with weakness in my left leg. My neurologist wants me to start medication now and my options are tecfidera or aubagio. I'm leaning towards ...
Read more : Tecfidera versus aubagio | Views : 596 | Replies : 1


RE MEDICINOVA PROVIDES UPDATE ON PHASE 2b TRAILS PMS

http://globenewswire.com/news-release/2 ... ve-MS.html
Dear friends MEDICINOV Inc. recently announced that it had 50% enrolment for the PHASE 2b clinical trail of MN-166(ibdilast) in progressive M.S patients and the trail is on track please read the rest attached
regards
seeva
Read more : RE MEDICINOVA PROVIDES UPDATE ON PHASE 2b TRAILS PMS | Views : 318 | Replies : 0


NEW CHEMICAL FOUND TO BE DUAL ABILITIES

FRIENDS This was on last friday radio national please listen http://mpegmedia.abc.net.au/rn/podcast/ ... 9_0636.mp3
regards
seeva
Read more : NEW CHEMICAL FOUND TO BE DUAL ABILITIES | Views : 469 | Replies : 1


Researchers investigating new treatment for MS

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology® Neuroimmunology & Neuroinflammation.

The phase I studies were the first to test the drug candidate in humans. Studies with animals showed that the drug, which is called anti-LINGO-1, or BIIB033, may be able to reverse the demyelination of the nerves. Anti-LINGO-1 blocks LINGO-1, a central nervous system ...
Read more : Researchers investigating new treatment for MS | Views : 499 | Replies : 0


Phase I trial of ALKS 8700 to treat multiple sclerosis begin

Phase I trial of ALKS 8700 to treat multiple sclerosis begins

Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS).

The trial will assess the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy volunteers......... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Phase I trial of ALKS 8700 to treat multiple sclerosis begin | Views : 581 | Replies : 0


Over-the-counter antihistamine, Tavist, being tested

http://clinicaltrials.gov/show/NCT02040298

Is anyone taking this over the counter antihistamine and seeing any improvement in their symptoms?
Read more : Over-the-counter antihistamine, Tavist, being tested | Views : 917 | Replies : 4


Could existing common medications help restore myelin in MS?

Could existing common medications help restore myelin in MS patients?

A common cold treatment and seven other drugs already approved for other conditions could help restore a protective coating eroded around neurons in multiple sclerosis patients, according to researchers led by a team at the University of California, San Francisco.

UCSF is spearheading a 50-patient clinical trial of the most promising drug — an over-the-counter antihistamine branded by Novartis as Tavist — that is expected ...
Read more : Could existing common medications help restore myelin in MS? | Views : 959 | Replies : 2


CAMBRIDGE UNIVERSITY DEVELOPED MS DRUG APPROVED BY WATCHDOG

http://www.bbc.com/news/uk-england-camb ... e-27594138
A new drug for treating M.S developed by cambridge university research read the site more information
regards
seeva
Read more : CAMBRIDGE UNIVERSITY DEVELOPED MS DRUG APPROVED BY WATCHDOG | Views : 683 | Replies : 0


Positive phase2 results reported for RPC1063 in relapsing MS

Receptos, Inc. announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis (RMS) met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development..... Read More ...
Read more : Positive phase2 results reported for RPC1063 in relapsing MS | Views : 580 | Replies : 0


 

Login  •  Register


Statistics

Total posts 222275 • Total topics 23085 • Total members 14615


Contact us | Terms of Service